middle.news
Tryptamine Therapeutics Launches Groundbreaking IV Psilocin Trial for Binge Eating Disorder
8:41am on Monday 21st of July, 2025 AEST
•
Healthcare
Read Story
Tryptamine Therapeutics Launches Groundbreaking IV Psilocin Trial for Binge Eating Disorder
8:41am on Monday 21st of July, 2025 AEST
Key Points
Patient recruitment started for first-ever IV psilocin trial targeting Binge Eating Disorder
Open-label study to enroll 12 adults in two dose cohorts with dosing this quarter
Trial conducted in partnership with Swinburne University, with results expected Q4 2025
BED is a highly prevalent disorder with significant psychiatric comorbidities
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
TYP
OPEN ARTICLE